Advertisement

Topics

LIDDS: NanoZolid® with immune-stimulating agent confirms efficacy in an additional cancer model

10:00 EST 10 Jan 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
LIDDS has successfully completed another preclinical study in mice assessing the feasibility of using the NanoZolid® drug delivery technology for intratumoral immunotherapy. Clear anti-tumor effects have been observed in another cancer model in m...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "LIDDS: NanoZolid® with immune-stimulating agent confirms efficacy in an additional cancer model "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...